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Calbindin (CB) is a calcium binding protein reported to protect dopaminergic neurons from
degeneration. Although a direct link between CB content and differential vulnerability of
dopaminergic neurons has long been accepted, factors other than CB have also been
suggested, particularly those related to the dopamine transporter. Indeed, several studies
have reported that CB levels are not causally related to the differential vulnerability
of dopaminergic neurons against neurotoxins. Here we have used dual stains for
tyrosine hydroxylase (TH) and CB in 3 control and 3 MPTP-treated monkeys to visualize
dopaminergic neurons in the ventral tegmental area (VTA) and in the dorsal and ventral
tiers of the substantia nigra pars compacta (SNcd and SNcv) co-expressing TH and CB.
In control animals, the highest percentages of co-localization were found in VTA (58.2%),
followed by neurons located in the SNcd (34.7%). As expected, SNcv neurons lacked CB
expression. In MPTP-treated animals, the percentage of CB-ir/TH-ir neurons in the VTA
was similar to control monkeys (62.1%), whereas most of the few surviving neurons in
the SNcd were CB-ir/TH-ir (88.6%). Next, we have elucidated the presence of CB within
identified nigrostriatal and nigroextrastriatal midbrain dopaminergic projection neurons. For
this purpose, two control monkeys received one injection of Fluoro-Gold into the caudate
nucleus and one injection of cholera toxin (CTB) into the postcommissural putamen,
whereas two more monkeys were injected with CTB into the internal division of the globus
pallidus (GPi). As expected, all the nigrocaudate- and nigroputamen-projecting neurons
were TH-ir, although surprisingly, all of these nigrostriatal-projecting neurons were negative
for CB. Furthermore, all the nigropallidal-projecting neurons co-expressed both TH and
CB. In summary, although CB-ir dopaminergic neurons seem to be less prone to MPTP-
induced degeneration, our data clearly demonstrated that these neurons are not giving rise
to nigrostriatal projections and indeed CB-ir/TH-ir neurons only originate nigroextrastriatal
projections.
Keywords: calbindin, Parkinson’s disease, nigroextrastriatal pathway, neuronal tracers, neuroprotection, MPTP
INTRODUCTION
Parkinson’s disease (PD) is characterized by a progressive and
selective loss of midbrain dopaminergic (DA) neurons. This cell
loss follows a heterogeneous pattern as described in PD patients.
The greatest loss of DA neurons is found in the substantia
nigra pars compacta (SNc, group A9), whereas DA neurons in
the ventral tegmental area (VTA, group A10) are known to be
less vulnerable (German et al., 1989; Damier et al., 1999a,b; Lu
et al., 2006). Within the SNc, neurons in the ventrolateral and
caudal regions are more prone to degenerate than those in the
rostromedial and dorsal region of the SNc. (German et al., 1989,
1992; Lu et al., 2006).
Animal models for PD showed a similar pattern of midbrain
DA neurons loss (German et al., 1988, 1996; Varastet et al., 1994;
Liang et al., 1996; Oiwa et al., 2003; Fitzpatrick et al., 2005). Sys-
temic administration of MPTP to non-human primates induces
a selective nigrostriatal degeneration mimicking the pattern of
differential vulnerability of DA neurons observed in PD patients;
the greatest loss being found in ventrolateral territories of the SNc
(Schneider et al., 1987; Schneider and Dacko, 1991; Varastet et al.,
1994).
It has been suggested that this selective vulnerability of mid-
brain DA neurons could be related with diverse differentia-
tion routes during embryonic development (Smits et al., 2006;
Smidt and Burbach, 2007), originating different DA phenotypes.
Although the mechanism responsible for the preferential loss of
DA neurons is still under discussion, a number of neuroprotec-
tive mechanisms have been suggested. Although several studies
appointed the calcium-binding protein known as calbindin (CB;
Gerfen et al., 1985, 1987; Yamada et al., 1990; Ng et al., 1996; Yuan
et al., 2013) as a putative neuroprotective agent, candidates other
than CB such as the vesicular monoamine transporter (VMAT2;
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Liu et al., 1992; Harrington et al., 1996; Miller et al., 1999;
Caudle et al., 2007; Afonso-Oramas et al., 2009) have also been
suggested.
The fact that CB-immunopositive neurons in the SNc are
relatively preserved in patients and animal models of PD (Yamada
et al., 1990; Lavoie and Parent, 1991; Ito et al., 1992; Damier
et al., 1999a; Choi et al., 2008; Yuan et al., 2013), have led
to the idea that CB could confer some neuroprotection to DA
neurons against degeneration (Gerfen et al., 1985, 1987; Yamada
et al., 1990; Ng et al., 1996; Yuan et al., 2013). CB regulates the
availability of calcium ions (Ca+2) within the cell, thus buffering
the calcium overload and thereby protecting the cell against
neurotoxicity (Reisner et al., 1992). In midbrain DA neurons the
Ca+2 channels are opened much more time than in any other
cell types (Wilson and Callaway, 2000), because they show an
unusual physiological phenotype; they are autonomously active
showing a pacemaking activity (Grace and Bunney, 1983). The
need to maintain Ca+2 homeostasis includes the coordination of
endoplasmatic reticulum pumps, the uptake of Ca+2 into mito-
chondria and lysosome function; these Ca+2 pathways interact
with the mitochondrial function and oxidative stress both of
which appears to be involved in the pathogenesis of PD (Schapira
et al., 1990; Selvaraj et al., 2009, 2012; Surmeier et al., 2011;
Davey and Bolaños, 2013). Bearing in mind all these data, the CB
theory hypothesized that the resilience of CB immunoreactive DA
neurons in the midbrain is due to the presence of calcium binding
proteins; which effectively sequester Ca+2 without using ATP, so
CB reduces vulnerability to mitochondrial toxins and seems to
confer resistance to the PD-related neurotoxic agents (German
et al., 1992; Ito et al., 1992; Damier et al., 1999b; Hurley et al.,
2013; Yuan et al., 2013).
Tract-tracing studies in the monkey showed that DA mid-
brain neurons also differ in their projection patterns (Haber
and Fudge, 1997; Smith and Kieval, 2000), nigrostriatal and
nigroextrastriatal projections (nigropallidal and the nigrosub-
thalamic) arise from different groups of midbrain DA neurons
(Fallon and Moore, 1978; Lindvall and Björklund, 1979; Lavoie
et al., 1989; Smith et al., 1989; Cossette et al., 1999; Hedreen,
1999; François et al., 2000; Jan et al., 2000; Smith and Kieval,
2000; Anaya-Martinez et al., 2006). The nigrostriatal projection
arises from the SNc, VTA and retrorubral area (RRA): (1) the
postcomissural putamen (sensorimotor striatum) is mainly tar-
geted by DA cells located in the ventral tier of the SNc; (2) the
limbic ventral striatum is innervated by DA neurons from the
VTA and dorsal tier of the SNc; and (3) the caudate nucleus
(associative striatum) is mainly innervated by DA neurons sit-
uated in the ventral tier of the SNc (Haber and Fudge, 1997;
François et al., 2000; Smith and Kieval, 2000). The external
and internal globus pallidus (GPi) as well as the subthalamic
nucleus receive sparse collaterals from the nigrostriatal pathway
but those nuclei also receive TH input from the nigroextrastriatal
projections (Lavoie et al., 1989; Hassani et al., 1997; Cossette
et al., 1999; Hedreen, 1999; François et al., 2000; Cragg et al.,
2004). The nigropallidal projection is originated in the SNc
and RRA (Jan et al., 2000), while the nigrosubthalamic projec-
tion arises from the SNc, VTA and RRA (Lavoie et al., 1989;
François et al., 2000). The nigroextrastriatal projections also show
a topographical organization similar to the one described in the
striatum (François et al., 2000; Jan et al., 2000; Rommelfanger and
Wichmann, 2010).
Different reports in MPTP-non-human primates have shown
that the cells in the midbrain area that are able to resist chronic
MPTP treatment are mostly DA neurons that express CB (CB-ir;
Lavoie and Parent, 1991; German et al., 1992). The fact that the
globus pallidus of MPTP-treated animals showed TH immunore-
active (TH-ir) sparing fibers (Varastet et al., 1994) suggests that
the DA surviving neurons in the midbrain are involved in the
nigroextrastriatal pathways instead of the nigrostriatal pathway
(Parent et al., 1990; Varastet et al., 1994).
The purpose of the present study was to identify the DA
midbrain neurons expressing CB in Macaca fascicularis, in control
and MPTP-treated animals. Once the TH-ir neurons that also
express CB-ir were identified in different midbrain areas, neu-
ronal tracers were used to disclose whether these neuronal pheno-
types were involved in the nigrostriatal and/or nigroextrastriatal
pathways.
MATERIAL AND METHODS
A total of ten naïve adult male Macaca fascicularis primates
(body weight 3.8–4.5 kg) were used in this study. Animal han-
dling was conducted in accordance with the European Council
Directive 2010/63/UE, as well as in agreement with the Society
for Neuroscience Policy on the Use of Animals in Neuroscience
Research. The experimental design was approved by the Ethical
Committee for Animal Testing of the University of Navarra. All
animals were captive-bred and supplied by R.C. Hartelust (The
Netherlands).
MPTP TREATMENT
The dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP; Sigma M0896) was administered
intravenously to three macaques at a concentration of 0.3 mg/kg
(injected weekly) until animals reached a stable parkinsonian
syndrome. The severity of the MPTP-induced parkinsonism was
evaluated using clinical rating scales (Kurlan et al., 1991) where
the highest score was 29. The clinical features used in this scale
included: facial expression (0–3), resting tremor (0–3), action or
intention tremor (0–3), posture (0–2), gait (0–3), bradykinesia
(0–3), balance/coordination (0–3), gross motor skills upper limb
(0–3), gross motor skills lower limb (0–3), defense reaction (0–2).
The MPTP-treated macaques reached a stable score between
19–23 points that was maintained over a period of 3 months of
MPTP washout.
STEREOTAXIC SURGERY, PERFUSION AND TISSUE PROCESSING
Surgical anesthesia was induced by intramuscular injection of
ketamine (0.5 mg/kg) and midazolam (5 mg/kg), resulting in
deep anesthesia over a period of 2–3 h. Local anesthesia was
implemented just before surgery by means of a 10% solution
of lidocaine. As prophylaxis they received a single subcutaneous
injection of metilprednisolone (10 mg/kg) and dexamethasone
(0.1 mg/kg) delivered at the end of the surgical procedure and
daily doses of intramuscular injection of enrofloxacin (5 mg/kg)
over a period of 7 days. Analgesia was achieved with a single
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subcutaneous injection of carprofen (4 mg/kg–0.08 ml/Kg) deliv-
ered at the end of the surgical procedure and repeated 24 and
48 h post-surgery. After surgery, animals were kept under constant
monitoring in single cages with ad libitum access to food and
water.
Stereotaxic coordinates for the putamen, the caudate and
GPi nuclei were taken from the atlas by Lanciego and Vázquez
(2012). During surgery, target selection was assisted by ventricu-
lography. Selected coordinates: caudate nucleus 1 mm rostral
to the anterior commissure, 4.5 mm lateral to the midline and
5 mm dorsal to the intercommisural plane; putamen nucleus
1 mm caudal to the anterior commissure, 11 mm lateral to
the midline and 2 mm ventral to the intercommissural plane.
GPi 4.5 mm caudal to the anterior commissure, 8 mm lateral
to the midline and 1.5 mm ventral to the intercommissural
plane.
Two monkeys received a single pressure-injection of 5 µl of
unconjugated cholera toxin subunit B (CTB, List Biological Labo-
ratories, Campbell, CA) through a Hamilton syringe (5 mg/ml in
0.01 M phosphate buffer (PB), pH 7.5) in the dorsolateral post-
commissural putamen. An additional single pressure-injection
of 0.5 µl of Fluorogold (FG) through a Hamilton syringe (10%
in 0.01 M PB (pH 7.5) was made in the head of the caudate
nucleus. Both injections were made in the same monkey and
in the same side of the brain. Two additional monkeys received
a single pressure-injection of 5 µl of CTB through a Hamilton
syringe (5 mg/ml in 0.01 M PB, pH 7.5) in the internal division of
the globus pallidus. Tracer delivery was accomplished in pulses
of 1or 0.1 µl every 2 min. Once completed, the microsyringes
were left in place for 15 min before withdrawal to minimize tracer
uptake through the injection tract.
Two weeks post-surgery, animals were anesthetized with an
overdose of 10% chloral hydrate and perfused transcardially.
The perfusates consisted of a saline Ringer solution followed by
3,000 ml of a fixative solution containing 4% paraformaldehyde
and 0.1% glutaraldehyde in 0.125 M PB, pH 7.4. Perfusion was
continued with 1,000 ml of a cryoprotectant solution containing
10% glycerin and 2% dimethylsulphoxide (DMSO) in 0.125 M
PB, pH 7.4. Once perfusion was completed, the skull was opened,
the brain removed and stored for 48 h in a cryoprotectant solution
containing 20% of glycerin and 2% DMSO in 0.125 M PB, pH
7.4. Finally, frozen serial sagittal or coronal sections (40 µm-
thick) were obtained on a sliding microtome and collected in
0.125 M PB cryoprotectant solution containing 20% of glycerin
and 2% DMSO in 0.125 M PB, pH 7.4, as 10 series of adjacent
sections.
DETECTION OF TRANSPORTED CTB AND FLUOROGOLD
Immunohistochemical detection of transported CTB and FG
was carried out on coronal sections. Sections were incubated
with a primary antibody against CTB raised in goat (1:2000;
List Biologicals, INC, 703) and rabbit antibody Anti-Fluorescent
Gold (1:2000; Chemicon, AB153), diluted in a solution contain-
ing 5% of normal donkey serum (NDS) (Jackson inmunore-
search Laboratories, 017-000-121), 5% normal swine serum
(Jackson immunoresearch Laboratories, 014-00-121), 0.04% tri-
ton X-100 in phosphate buffer (PBS) pH 7.4 overnight. After
rinsing in PBS, sections were incubated for 2 h in a solution
containing 5% of NSwS, 5% NDS, swine anti-rabbit IgG (1:50,
Dako, Z0196) and donkey anti-goat (Jackson Immunoresearch,
705-065-147) diluted in PBS for 90 min; after washes sec-
tions were incubated in a solution containing 5% NDS and
Goat PAP (1:600 Sigma, P1901) and afterwards washed in PBS
and visualized in brown with DAB (Sigma, D5637). Section
were washed in PBS and incubated in a solution containing
5% NSwS and Rabbit PAP (1:50 Dako, Z0113 diluted in PBS
and visualized using Vector VIP Peroxidase (HRP) Substrate
Kit (Vector laboratories, SK-4600). Sections were mounted on
gelatin-coated glass slides, dried at RT and coverslip with Dpex
(VWR International).
DETECTION OF TRANSPORTED CTB AND FG COMBINED WITH TH AND
CB IMMUNOFLUORESCENCE
The following primary antibodies were used in double
inmunofluorescence: (1) a mouse anti-calbindin-D-28K (1:2000,
Sigma, C9848); (2) a goat anti- TH (1:50, Santa Cruz, sc-
7847); (3) a rabbit anti-Fluorescent Gold Antibody (1:2000,
Chemicon, AB153); and (4) a rabbit anti-CTB (1:2000, Genway,
18-272-195906).
In the present study we have used the following secondary
antibodies: Alexa Fluor® 633 Donkey Anti-Mouse IgG (1:200,
Molecular Probes A 21082); Alexa Fluor® 546 donkey anti-goat
IgG (1:200, Molecular Probes A 11056), Alexa Fluor® 488 donkey
anti-rabbit IgG (1:200, Molecular Probes A 21206), biotinylated
Donkey anti-rabbit IgG (1:600, Jackson Laboratories, 711-066-
152) and biotinylated Donkey anti-mouse IgG (1:600, Jackson
Laboratories, 715-066-150).
For single and triple immunohistochemistry, free-floating sec-
tions were incubated in a blocking solution containing 5% of NDS
and 0.04% triton X-100 in PBS pH 7.4 for an hour. After that,
sections were incubated overnight at room temperature with the
appropriate primary antibody or mix of antibodies, diluted in a
solution of 5% NDS, 0.04% triton X-100 in PBS.
For single immunohistochemistry, after rinsing in PBS, sec-
tions were sequentially incubated with the appropriate secondary
antibody diluted in a solution containing 5% of NDS in PBS for
2 h and afterwards washed in PBS. Finally sections were incubated
in a solution of HRP-conjugated streptavidin (1:5000, Sigma,
E2886) diluted in PBS for 90 min and visualized in brown with
DAB (Sigma, D5637).
For triple immunofluorescence, after rinsing with PBS sec-
tions were incubated with the appropriated fluorescent secondary
antibodies and diluted in a solution containing 5% NDS in PBS
for 2 h.
Finally, sections were rinsed in PBS and mounted on Super-
Frost Ultra Plus® slides, dried at RT and coverslip with Dpex
(VWR International).
SECTIONS SAMPLED AND QUANTIFICATION OF TH+/CB+
CO-LOCALIZATION
One series of sections from three control and three MPTP-treated
macaques were used for quantifying TH+/CB+ co-localization
in double-stained material. Briefly, three equally-spaced coronal
sections through the mesencephalon (1.5 mm apart from each
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other) were entirely scanned under the confocal microscope. One
section was taken at the level of the exit of the third cranial
nerve to properly elucidate the boundaries between the SNc and
VTA. Next, two more rostral and caudal coronal sections (1.5 mm
rostral and caudal to the exit of the third cranial nerve, respec-
tively) were chosen for counting purposes. The percentages of
co-localization were gathered from 2,615 +/− 640 TH+ neurons
in control macaques and from 1,112 +/− 145 TH+ neurons in
MPTP-treated animals.
CONFOCAL VISUALIZATION SETTINGS
Stained samples (immunofluorescence and PLA) were inspected
under a Zeiss 510 Meta confocal laser-scanning microscope
(CLSM). To ensure appropriate visualization of the labeled ele-
ments and to avoid false positive results, the emission from the
argon laser at 488 nm was filtered through a band pass filter of
505–530 nm and color-coded in green. The emission following
excitation with the helium laser at 543 nm was filtered through a
band pass filter of 560–615 nm and color coded in red. Finally,
a long-pass filter of 650 nm was used to visualize the emis-
sion from the helium laser at 633 nm and color coded in pale
blue.
RESULTS
TH AND CB EXPRESSION IN CONTROL AND MPTP-TREATED MONKEYS
All three monkeys intoxicated with MPTP developed a stable
parkinsonian syndrome between 5 and 8 months after the ini-
tiation of MPTP administration, scoring between 19–23 points
in the accumulative Kurlan scale (Kurlan et al., 1991). The
immunohistochemistry for TH confirmed the extension of the
nigrostriatal damage induced in the three monkeys treated with
MPTP, when compared with the TH stain in the control monkeys
(Figure 1).
Overall, the pattern of degeneration in the ventral midbrain
and striatum was similar for the three monkeys. As expected,
the caudate and putamen of control monkeys showed numerous
and intense TH-ir (Figure 1A), whereas MPTP-treated monkeys
showed a marked reduction in TH density in both caudate and
putamen nuclei (Figure 1I). In control monkeys, TH-ir neu-
rons were easily noticed in the dorsal and ventral tiers of the
SNc (Figures 1B–D). MPTP treatment induced a severe loss of
dopaminergic neurons, although few TH-ir cells within the dorsal
and ventral tiers of the SNc were still visible. (Figures 1J–L). By
contrast, only very small differences in TH immunoractivity were
observed in the VTA when comparing control and MPTP-treated
monkeys (Figures 1C,K).
CB immunohistochemistry in control and MPTP-treated
monkeys was carried out using sections adjacent to those stained
for TH. The striatum, SNc (rostral, medial and caudal), and VTA
showed similar levels of CB-immunoreactivity (CB-ir) in both
control and MPTP-treated monkeys (Figure 1).
Double-labeling stains for TH and CB were carried out in the
VTA and SNc in control and MPTP-treated monkeys (Figure 2).
In control animals, and in keeping with previous studies, the
highest percentage of co-localization was found in the VTA, where
58.2% of TH-ir neurons also showed immunoreactivity for CB
(Figure 2). At the level of the SNc, 34.7% of TH-ir neurons
from the dorsal tier (SNcd, medial and lateral territories) also
expressed CB-ir, whereas TH-ir neurons in the ventral tier did
not colocalized with CB. As expected, TH-ir neurons located in
the ventral tier (SNcv) lacked CB immunoreactivity (Figure 2).
MPTP-treated macaques showed a similar percentage of TH/CB
colocalization in the VTA (62.1%). Moreover, most of the sur-
viving TH-ir neurons (88.6%) in the SNcd also expressed CB
(Figure 2). Similar to what was found in the SNcv for control
macaques, TH-ir neurons in the SNcv did not expressed CB in
MPTP-treated animals (Figure 2).
DISTRIBUTION OF NIGROSTRIATAL-PROJECTING NEURONSWITHIN
THE SNc AS SEENWITH RETROGRADE TRACERS
Control animals received two injections of the retrograde trac-
ers FG and CTB into the caudate and putamen nuclei, respec-
tively. Tracer leakage through the injection tracts was not
observed in any of the injected animals (Figures 3A,B). In
all cases, CTB- and FG -labeled neurons were found through-
out rostral, medial and caudal territories of the ipsilateral SNc
(Figures 3C–E), and in the ipsilateral VTA. Labeled neurons
were distributed in clusters across the entire rostrocaudal extent
of the SNc. Although both types of projection neurons were
intermingled with each other in all clusters, double-labeled
neurons were never observed (Figures 3F–K). Few scattered
cells labeled with either CTB or FG were also found in the
VTA.
EXPRESSION OF TH AND CB IN IDENTIFIED NIGROSTRIATAL
DOPAMINERGIC NEURONS
To elucidate the presence of CB-ir within identified nigrostriatal-
projecting midbrain dopaminergic neurons, triple immunofluo-
resce stains detecting TH, CB and FG or CTB were conducted
in control animals (Figures 4, 5). Following the deposit of FG
in the caudate nucleus, labeled neurons were found in both
the dorsal and ventral tiers of the SNc, as well as in the VTA
(Figure 4). All FG immunoreactive neurons (FG-ir) expressed
TH. As described above, CB-ir was only found in a subpopulation
of TH-ir neurons in the SNcd and in the VTA (Figure 4). How-
ever, none of the TH-ir/CB-ir neurons in SNcd and VTA showed
FG labeling.
Similar results were obtained following the delivery of CTB
in the putamen nucleus. All the observed CTB immunoreac-
tive neurons (CTB-ir) were identified as TH-ir in SNcd, SNcv
and VTA territories. Furthermore, all CB-ir neurons were also
positive for TH. Similarly to what was observed for nigro-
caudate projection neurons, none of the nigro-putaminal pro-
jection neuron did express CB (Figure 5). In other words,
our tract-tracing data indicated that although the identified
nigrostriatal-projecting neurons (innervating wither the caudate
or the putamen nucleus) were all TH-ir, all these neurons com-
pletely lacked CB immunoreactivity.
EXPRESSION OF TH AND CB IN NEURONS GIVING RISE TO
NIGROEXTRASTRIATAL PROJECTIONS
Although the data gathered from identified nigrostriatal neu-
rons showed that these neurons did not contain CB, the basal
ganglia territories innervated by neurons co-expressing TH and
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FIGURE 1 | Distribution patterns of TH and CB immunoreactivity
in caudate and putamen, SNc and VTA in control and
MPTP-treated monkeys. (A–D) TH immunohistochemistry in control
monkeys in striatum (A), rostral, medial, and caudal SNc (B–D) and
VTA. (1–4) Insets taken at higher magnification of rostral (1), medial
(2), and caudal (3) SNc and VTA (4) showing TH-ir profiles. (E–H) CB
immunoreactivity in striatum (E), rostral, caudal, and medial (F–H) SNc
and VTA. (5–8) Higher magnification insets of CB-ir cells in rostral (5),
medial (6) and caudal (7) SNc, and VTA (8). (I–L) Extent of
MPTP-induced dopaminergic depletion. The levels of TH in the
striatum and SN that typically characterizes a control primate (A–D) are
clearly reduced in the MPTP-treated monkeys (I–L). (9–12) Higher
magnification insets of TH-ir cells in the rostral (9), medial (10) and
caudal (11) SNc as well as in the VTA (12), showing a reduction of the
TH immunoreactivity compared with control monkeys (1–4). (M–P)
calbindin immunohistochemistry in striatum (M), rostral, medial, and
caudal SNc (N–P) and VTA. (13–16) Insets taken a higher
magnification from rostral (13), medial (14), and caudal SNc (15) and
VTA (16) showing the presence of CB-ir cells in these areas. Unlike the
TH expression, CB immunoreactivity did not changed between control
and MPTP-treated monkeys. Scale bars: 1,000 µm in panels (A, E, I
and M); 250 µm in panels (B–D, F–H, J–L and N–P); 25 µm in panels
(1–16). Abbreviations: substantia nigra, pars compacta (SNc), ventral
tegmental area (VTA), putamen (Put), caudate nucleus (CN), external
division of the globus pallidus (GPe), internal capsule (ic), anterior
commissure (ac).
CB remained to be elucidated. Accordingly, two more control
primates were injected with CTB in the internal section of
the globus pallidus (GPi) to further identify nigroextrastriatal
neurons innervating the GPi (Figure 6A). Tracer leakage through
the needle tract was not seen in any of the injected animals
(Figure 6A).
Frontiers in Neuroanatomy www.frontiersin.org December 2014 | Volume 8 | Article 146 | 5
Dopeso-Reyes et al. Calbindin and dopaminergic vulnerability
FIGURE 2 | Double immunofluorescent detection of TH and CB in VTA
and SNc in control and MPTP-treated monkeys. At the level of the VTA in
control macaques (A–A”), 58.2% of the CB-ir neurons are also TH-ir, and
62.1% in MPTP-treated animals (B–B”). When considering the dorsal tier of
the SNc (SNcd, medial and lateral territories) of control animals (C–C” and
E–E”) the percentage of co-localization is estimated as 34.7% (arrowheads).
By contrast, in MPTP-treated macaques and besides a substantial loss of
TH-ir neurons, most of the surviving dopaminergic neurons expressed CB
(arrowheads in D–D” and F–F”). The percentage of TH-ir/CB-ir neurons
increased up to 88.6%. In other words, dopaminergic neurons from the SNcd
containing CB are less prone to degenerate following MPTP insult. At the
level of the ventral tier of the SNc (SNcv) none of the TH+ neurons expressed
CB in control animals (G–G”). Panels (H–H”) are taken from the boundaries
between SNcd and SNcv, since most -if not all- of the TH-ir neurons in the
SNcv degenerated following MPTP treatment because of the lack of CB in
these cells. Scale bar is 25 µm in all panels.
The simultaneous triple stain for TH, CB and CTB showed that
TH and CB co-localized in all the observed CTB-ir neurons. In
other words, the observed nigro-pallidal projection neurons in the
VTA and SNcd were all CB-ir/TH-ir (Figure 6).
DISCUSSION
CB have been proposed as a resilience factor in the DA neurons
of the midbrain; the presence of this calcium binding pro-
tein could efficiently buffer Ca+2, therefore reducing vulnera-
bility to mitochondrial toxins, ultimately conferring resistance
to the PD-related toxins (Gerfen et al., 1985, 1987; Yamada
et al., 1990; German et al., 1992; Ito et al., 1992; Ng et al.,
1996; Damier et al., 1999b; Hurley et al., 2013; Yuan et al.,
2013).
In the present work we have studied the content of CB within
identified subpopulations of TH-ir cells located in the VTA and
the SNc. Our results showed the presence of CB in TH-ir cells
located in the VTA and in the SNcd, whereas CB was absent
in the TH-ir cells of the SNcv. We also observed the presence
of CB within the few TH-ir surviving cells of the SNcd and
in the VTA from MPTP-treated monkeys. These results are in
keeping with earlier reports (Gerfen et al., 1987; Yamada et al.,
1990; Lavoie and Parent, 1991; Varastet et al., 1994; Damier
et al., 1999a,b). However, after identifying different subpopu-
lations of nigral efferent neurons innervating the caudate, the
putamen or the internal division of the globus pallidus, we have
found that nigrostriatal-projecting neurons were all CB negative,
whereas co-localization of TH and CB was only found in those
nigral neurons giving rise to nigroextrastriatal -nigropallidal-
projections.
The highest percentage of co-localization of TH and CB
was observed in the VTA (58.2%), followed by the SNcd
(34.7%), similarly to previous studies in macaques report-
ing a co-localization rate of 43% in the VTA and 22% in
the SNcd (Lavoie and Parent, 1991). In keeping with Lavoie
and Parent (1991), co-localization of TH and CB was only
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FIGURE 3 | Different types of nigrostriatal-projecting neurons
identified following the delivery of retrograde tracers in the head of
the caudate nucleus (A; injection of FG) and in dorsolateral territories
of the postcommissural putamen (B; CTB deposit). Both injections are
restricted to the targeted area, without any noticeable tracer leakage
through the injection tract. (C–E) coronal sections through the substantia
nigra taken from rostral (C), medial (D) and caudal (E) levels. Neurons
innervating either the caudate nucleus (purple-stained; labeled with FG) or
the putamen (brown-stained; labeled with CTB) are distributed in clusters
containing both subtypes of neurons intermingled with each other. (F–K)
Insets taken from (C–E) at higher magnification to better appreciate the
cellular composition of the clusters containing projection neurons. It is
worth noting that double-labeled cells, e.g., neurons innervating both the
(Continued )
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FIGURE 3 | Continued
caudate and the putamen were never noticed. Scale bar is 2,000 µm in
panels (A) and (B); 500 µm in panels (C–E), and 100 µm in panels (F–K).
Abbreviations: putamen (Put), caudate nucleus (CN), external division of the
globus pallidus (GPe), internal capsule (ic), anterior commissure (ac).
found in the SNcd, since SNcv neurons lacked CB expres-
sion. Those results are also comparable to the TH and CB
immunoreactivities observed in the human midbrain, where
CB-ir cells were only found in the VTA and SNcd (Damier et al.,
1999b).
As expected, the MPTP treatment produced severe dopamin-
ergic depletion in the macaque striatum (German et al., 1988;
Varastet et al., 1994; Jackson-Lewis et al., 1995; Mazloom and
Smith, 2006; Rico et al., 2010), together with a gradient of
neuronal loss in midbrain dopaminergic nuclei (German et al.,
1988; Lavoie and Parent, 1991; Rico et al., 2010). After MPTP
administration, TH-ir neurons in the SNcv are almost com-
pletely removed, followed by neurons in the SNcd, and to a
FIGURE 4 | Nigrostriatal neurons innervating the caudate
nucleus. Following the delivery of FG in the head of the caudate
nucleus, retrogradely-labeled neurons (green channel) were found in
the SNcd (C), in the SNcv (G) and to a lesser extent in the VTA (K).
All these FG-ir neurons are TH-ir and negative for CB. (A’–C’) Insets
taken from (A–D) showing one FG+/TH+ neuron, one CB-ir/TH-ir
neuron as well as another neuron single-stained for TH only. It is
worth noting that FG-ir/TH-ir/CB-ir neurons were never seen. Scale
bar is 25 µm for panels (A–D, E–H and I–L) and 5 µm in panels
(A’–D’).
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FIGURE 5 | Nigrostriatal neurons innervating the putamen
nucleus. Following the delivery of CTB in dorsolateral territories of the
postcommissural putamen, retrogradely-labeled neurons (green
channel) were found in the SNcd (C), in the SNcv (G) and to a lesser
extent in the VTA (K). All these CTB-ir neurons are TH-ir and negative
for CB. (A’–C’) Insets taken from (A–D) showing one CTB-ir/TH-ir
neuron, two CB-ir/TH-ir neurons as well as few more neurons
single-stained for TH only. It is worth noting that FG-ir/TH-ir/CB-ir
neurons were never seen. Scale bar is 25 µm for panels (A–D, E–H
and I–L) and 5 µm in panels (A’–D’).
lesser extent those dopaminergic neurons in the VTA. This
heterogeneous pattern of cell loss properly mimicked the one
observed in PD patients (German et al., 1988, 1996; Varastet
et al., 1994; Liang et al., 1996; Oiwa et al., 2003; Fitzpatrick
et al., 2005). Comparing control and MPTP-treated macaques,
similar percentages of TH/CB co-localization were found in the
VTA (58.2 vs. 62.1, respectively), whereas at the level of the
SNcd, most of the surviving dopaminergic neurons expressed CB
following MPTP treatment (88.6% compared to 34.7% in control
animals).
Although these data supported the potential neuroprotective
effect of CB against MPTP-induced dopaminergic cell degen-
eration, data gathered from the retrograde tracing studies con-
ducted here envisioned a different argument by showing that
nigrocaudate- and nigroputaminal-projecting TH-ir neurons did
not expressed CB in the VTA and in the SNcd nuclei. In
other words, TH-ir/CB-ir neurons in VTA and SNcd do not
innervate the caudate/putamen. Data provided here showed
that nigrostriatal-projecting neurons lacked CB, whereas those
expressing CB (the most resistant ones against MPTP) were
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FIGURE 6 | Nigroextrastriatal neurons innervating the internal division of
the globus pallidus (GPi). Following the delivery of the retrograde tracer
CTB (A, B), very few CTB-labeled neurons were found in the SNcd and in VTA
(E, E’; I, I’). It is worth noting that nigropallidal-projecting neurons were never
found in SNcv. Even at low magnification (panel A), a substantial number of
CTB-labeled neurons were easily noticed in the caudate nucleus and to a
lesser extent in medial territories of the putamen. At the level of the SNcd
(panels C–F’), all CTB-ir neurons (green channel) were also positive for both
TH and CB. The same holds true when considering the VTA area, since all the
VTA neurons projecting to GPi co-expressed CTB, TH and CB (panels G–J’).
Scale bar is 25 µm in panels (C–F and G–J) and 5 µm in panels (C’–F’ and
G’–J’).
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those neurons innervating the GPi through nigroextrastriatal
projections. It is worth noting that TH-ir fibers are still observed
in the GPi after chronic MPTP treatment (Parent et al., 1990;
Lavoie and Parent, 1991; Varastet et al., 1994) and indeed ear-
lier reports already suggested that nigroextrastriatal-projecting
dopaminergic neurons are less prone to MPTP-induced degen-
eration (Schneider et al., 1987; Parent et al., 1990; Schneider
and Dacko, 1991; Varastet et al., 1994). Nevertheless, it is
worth noting that the CTB retrograde tracer deposits made
here were all located in the dorsolateral postcommissural puta-
men and therefore the potential co-localization of CB and
TH in VTA/SNcd neurons innervating striatal territories other
than the dorsolateral postcommissural putamen cannot be ruled
out. Furthermore, nigroextrastriatal targets other than the GPi
nucleus such as the subthalamic nucleus and the external
division of the globus pallidus were not investigated in this
study.
CONCLUDING REMARKS
The potential role of the nigroextrastriatal system in PD
pathophysiology has long been neglected (Rommelfanger and
Wichmann, 2010) and indeed some studies have suggested that
this system plays an important role in the early compensatory
changes in PD (Obeso et al., 2004). Here we have found that
midbrain dopaminergic neurons innervating extrastriatal targets
were the only ones containing CB. Data reported here sustain
the presence of a potential imbalance between the nigrostriatal
and nigroextrastriatal systems in advanced diseases states. It seems
clear that dopaminergic inputs reaching the GPi nucleus are better
preserved that striatal dopaminergic innervation. Compared to
the early degeneration of the nigrostriatal system, the nigroex-
trastriatal system is less prone to degenerate, a phenomenon that
merits further research efforts in order to properly elucidate their
role both in the normal and diseased basal ganglia.
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